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Shigellosis is an important disease in the developing world, where about 90 million people become infected with Shigella spp.
each year. We previously demonstrated that the type three secretion apparatus (T3SA) proteins IpaB and IpaD are protective
antigens in the mouse lethal pulmonary model. In order to simplify vaccine formulation and process development, we have eval-
uated a vaccine design that incorporates both of these previously tested Shigella antigens into a single polypeptide chain. To de-
termine if this fusion protein (DB fusion) retains the antigenic and protective capacities of IpaB and IpaD, we immunized mice
with the DB fusion and compared the immune response to that elicited by the IpaB/IpaD combination vaccine. Purification of
the DB fusion required coexpression with IpgC, the IpaB chaperone, and after purification it maintained the highly -helical
characteristics of IpaB and IpaD. The DB fusion also induced comparable immune responses and retained the ability to protect
mice against Shigella flexneri and S. sonnei in the lethal pulmonary challenge. It also offered limited protection against S. dysen-
teriae challenge. Our results show the feasibility of generating a protective Shigella vaccine comprised of the DB fusion.
Shigellosis is a severe gastrointestinal disease caused by Shigellaspp. This disease is characterized by fever, bloody diarrhea,
and tenesmus. Recent calculations estimate the annual rate of Shi-
gella infections at 90 million, with 100,000 deaths per year (1).
An important number of these infections occur in children under
5 years old living in developing countries (2). Other at-risk pop-
ulations include military personnel deployed abroad (3) and ref-
ugees (4). Implications of this disease include severe impairment
of child development and nutrition (5), as well as an important
mortality index (2).
Four different species of Shigella have been described (6): S.
flexneri, S. sonnei, S. boydii, and S. dysenteriae. Modifications in the
O antigen give rise to about 50 serotypes (6, 7). The predominance
of specific serotypes varies both geographically (8) and during the
course of a single outbreak (9), complicating the epidemiology of
shigellosis. Immune responses against Shigella during natural in-
fection are predominantly serotype specific, in part due to the high
immunodominance of bacterial lipopolysaccharide (LPS) (10,
11). This dominance results in poor cross-reaction between dif-
ferent Shigella serotypes, thus opening the possibility of subse-
quent reinfections by Shigella organisms bearing different O anti-
gens.
Shigella infection requires the use of a highly conserved type
three secretion system (T3SS) encoded on a virulence plasmid
present in all Shigella species. After crossing the intestinal barrier
via M cells, Shigella is taken up by macrophages; however, it
escapes these phagocytes by inducing apoptosis mediated by the
T3SS translocator IpaB (12). Shigella then uses the T3SS to inject
protein effectors via the basolateral side of epithelial cells to pro-
mote bacterial entry. The pathogen lyses the resulting phagosome,
replicates, and spreads to adjacent cells. Control of type III secre-
tion occurs at the tip of the secretion apparatus needle by the
activity of IpaD along with IpaB (13, 14).
Despite long-standing efforts, a Shigella vaccine is still not
available (7, 15). Several groups have explored different ap-
proaches in the search of a Shigella vaccine. These include live
attenuated strains of Shigella (16), LPS-protein conjugates (17),
mixtures of subunit components (18), and recombinant proteins
(19). Our hypothesis is that a vaccine comprised of highly con-
served protein antigens would provide broad, serotype-indepen-
dent protection, thus bypassing the need to consider multiple se-
rotypes as are needed for vaccines that target LPS or O antigen. We
have previously demonstrated the protective efficacy of S. flexneri
2a-derived IpaB and IpaD, components of the T3SS (20), when
included in a vaccine formulation incorporating the novel muco-
sal adjuvant dmLT and delivered intranasally (20), orogastrically
(21), or intramuscularly (22) using monophosphoryl lipid A
(MPL) and alum hydroxide as adjuvants. The IpaB/IpaD subunit
vaccine elicited a strong systemic immunity, with the presence of
antibody-secreting cells in various compartments, as well as elic-
iting specific cytokine-secreting cells. Protection is achieved
against a homologous strain of S. flexneri and a heterologous
strain of S. sonnei in the mouse pneumonia model. Given that
children in low-resource countries are a primary target of a Shi-
gella vaccine, the ultimate vaccine formulation must be inexpen-
sive. To reduce the cost of an IpaB- and IpaD-based vaccine and
simplify manufacture and formulation, we created a genetically
fused IpaD-IpaB protein (DB fusion). The approach of using a
fusion of protective antigens has been explored successfully with
other subunit vaccines, including LcrV, an IpaD homolog (23–
25). In this study, the DB fusion elicited immune responses of a
magnitude similar to those generated by a combination of sepa-
Received 25 July 2013 Returned for modification 5 September 2013
Accepted 15 September 2013
Published ahead of print 23 September 2013
Editor: S. M. Payne
Address correspondence to Wendy L. Picking, wendy.picking@okstate.edu.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/IAI.00859-13
4470 iai.asm.org Infection and Immunity p. 4470 – 4477 December 2013 Volume 81 Number 12
 on A









rate IpaB and IpaD proteins. Interestingly, higher cytokine levels
were detected when cells from mice immunized with the DB fu-
sion were stimulated. In addition, mice were protected in the le-
thal pulmonary challenge (26, 27) using S. flexneri, S. sonnei, and
S. dysenteriae. Therefore, this novel fusion protein represents an
efficient alternative for vaccination against shigellosis in humans.
MATERIALS AND METHODS
Materials. pET plasmids, ligation mix, and competent Escherichia coli
were from EMD Millipore (Billerica, MA). Oligonucleotides were from
IDT (Coralville, IA). Restriction endonucleases were from New England
BioLabs (Ipswich, MA). HisTrap Crude FF immobilized-metal affinity
chromatography (IMAC) columns and Q FF anion-exchange columns
were from GE Healthcare (Piscataway, NJ). n-Octyl-oligo-oxyethylene
(OPOE) was from Enzo Life Sciences (Farmingdale, NY).
Generation of plasmids for expression of the DB fusion in E. coli.
ipaD was amplified from D/pET15b (28) by PCR using a 5= primer with an
NdeI restriction site and a 3= primer with an XhoI restriction site, while
ipaB was amplified from B/pET15b (29) using a 5= primer with an XhoI
site and a 3= primer with a BamHI site. The PCR products were digested by
the appropriate restriction endonucleases and ligated into pET28b. The
ligation reaction was used to transform E. coli NovaBlue. The resulting
DB/pET28b and ipgC/pACYCDuet-1 were cotransformed into E. coli
Tuner(DE3) for coexpression (Fig. 1A).
Protein purification and sample preparation. DB/pET28bipgC/
pACYCDuet-1//Tuner(DE3) bacteria were grown in autoinduction me-
dium (30) containing kanamycin (50 g/ml) and chloramphenicol (25
g/ml) for 16 to 18 h. Purification of the DB fusion was done as previously
described for IpaB (20, 31). Briefly, bacteria were collected by centrifuga-
tion, resuspended in IMAC binding buffer containing protease inhibitors
(Roche, Basel, Switzerland), and lysed; the suspension was clarified by
centrifugation and the supernatant containing the DB Fusion/IpgC com-
plex purified by IMAC. After further purification using a Q FF anion-
exchange chromatography column, OPOE was added to 0.5% to release
the IpgC. The His-tagged DB fusion was separated from IpgC using an
IMAC column with OPOE at 0.5% in all buffers and dialyzed into phos-
phate-buffered saline (PBS) with 0.5% OPOE. IpaB and IpaD were puri-
fied (32). Protein concentrations were determined by the A280 (33).
CD. Far-UV circular-dichroism (CD) spectra were collected (34).
Briefly, a Jasco J-815 spectropolarimeter fitted with a Peltier temper-
ature controller (Jasco Inc., Easton, MD) was used to collect spectra
from 190 nm to 260 nm through a 0.1-cm-path-length quartz cuvette.
FIG 1 Biophysical analysis of the DB fusion. (A) Construct harboring the IpaD/IpaB fusion. Restriction sites used for cloning are shown along a map of pET28b.
(B) Comparative SDS-PAGE with IpaB, IpaD, and DB fusion proteins is shown with molecular mass markers, in kilodaltons, indicated to the left. (C) The CD
spectra for IpaB in 0.5% OPOE, IpaD in PBS, and the DB fusion prepared in 0.5% OPOE all indicate predominantly -helical content with the mean residue
molar ellipticity ([q]R) values (measured in degrees cm
2 per decimol). (D) Thermal unfolding of the secondary structures of the DB fusion, IpaB, and IpaD as a
function of temperature is shown.
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Samples were kept at 10°C and scanned at 50 nm/min with a 1-nm
spectral resolution and a 2-s data integration time. All spectra are an
average of three measurements. Secondary-structure thermal stability
was determined by the monitoring the CD signal at 222 nm as the
temperature was increased from 10 to 90°C. The temperature ramp
rate was 15°C/h, and data were collected every 2.5°C. All protein solu-
tions were made to 0.5 mg/ml in phosphate citrate buffer, pH 7.4, with
0.5% OPOE included for IpaB and the DB fusion. CD signals were
converted to mean residue molar ellipticity.
Mice and immunizations. Six- to eight-week-old female BALB/c mice
(Charles River Laboratories, Wilmington, MA) were used. Mice were
anesthetized and vaccinated intranasally using 30 l (20). IpaB (13 g)
combined with IpaD (7 g) or the DB fusion (20 g) was admixed with
dmLT (2.5 g). These doses represent equimolar concentrations of anti-
gens. Mice that received an adjuvant or vehicle alone were included as
controls. Vaccine was delivered at days 0, 14, and 28.
Specific IgG antibodies. Antibodies specific for IpaB and IpaD were
determined by enzyme-linked immunosorbent assay (ELISA) (20).
Briefly, 96-well plates coated with IpaB or IpaD (1 g/ml in PBS) were
blocked overnight with PBS with 10% milk. Each well was incubated with
serum for 1 h at 37°C. After the plates were washed with PBS-Tween
(0.05%), secondary antibody (KPL, Gaithesburg, MD) was added for 1 h
at 37°C. Horseradish peroxidase (HRP) substrate was added, and the re-
action was stopped with H3PO4. Endpoint titers were calculated and rep-
resented as ELISA units (EU) per ml.
Stool IgA. Fresh fecal samples (3 to 5 pellets/mouse) were collected.
Each sample was resuspended in 10% (wt/vol) PBS with 0.2% NaN3. The
supernatant was clarified by centrifugation, and phenylmethylsulfonyl
fluoride (PMSF) was added to 1 mM. IgA levels were determined by
ELISA with an anti-IgA antibody (Southern Biotech, Birmingham, AL).
Endpoint titers were calculated as described above.
ASCs. Antibody-secreting cells (ASCs) were determined (20). Briefly,
cell suspensions were obtained by homogenizing through a nylon mesh
(BD Biosciences, San Diego, CA) the organs from five mice per group.
Samples were incubated with 5 g/ml of IpaB or IpaD for 24 h at 37°C.
After samples were washed with PBS-Tween, antibodies against IgG or
IgA were added. Trueblue (KPL) was used as a substrate in an agarose
overlay. Spots were counted under a stereomicroscope by 2 individuals,
and a mean of quadruplicate wells was expressed as specific ASCs per 106
cells.
IFN- ELISPOT. Splenocyes were collected from five mice per group
at day 56. Cells were incubated for 48 h at 37°C with 5 g/ml IpaB or IpaD
in plates coated with antibodies against IFN-. An enzyme-linked immu-
nosorbent spot (ELISPOT) assay was performed (BD Biosciences). Spots
were counted as described above and expressed as spot-forming cells
(SFC) per 106 cells.
Cytokine determinations. Splenocytes (obtained at day 56) were in-
cubated with 10 g/ml of IpaB, IpaD, or PBS for 48 h at 37°C. Secreted
interleukin 17 (IL-17) levels were measured using the DuoSet ELISA de-
velopment kit (22) or using a Th1/Th2 multiplex cytokine plate (Meso
Scale Discovery, Gaithersburg, MD).
Challenge. Shigella flexneri 2457T, Shigella sonnei 53G, and Shigella
dysenteriae serotype Sd1617 were grown overnight at 37°C in tryptic soy
agar with 0.05% Congo red. Ten colonies were picked and grown in tryp-
tic soy broth (EMD Millipore) at 37°C in agitation until reaching an A600
of 1. Bacteria were centrifuged and resuspended in PBS. On day 56, mice
were challenged by delivery of Shigella intranasally (26, 27). The doses,
administered in 30 l, were 6 106 CFU for S. flexneri, 2.1 106 CFU for
S. sonnei, and 7.5 106 CFU for S. dysenteriae. Changes in health and
weight loss were closely monitored for 14 days. Mice that became too sick
or remained below 80% of their starting weight for more than 48 h were
humanely euthanized. Animals were housed and handled in agreement
with Oklahoma State University Institutional Animal Care and Use Com-
mittee practices (protocol AS-10-6).
Statistical analysis. GraphPad Prism 5.04 was used to generate graph-
ics and statistical comparisons. Differences were analyzed using t test.
Survival plots were analyzed using log rank tests. A P value of less than 0.05
was considered significant for all comparisons. Vaccine efficacy was cal-
culated by using the formula efficacy  (ARU 	 ARV)/ARU  100, where
ARU is attack rate in the unvaccinated group and ARV is attack rate in the
vaccinated group (35).
RESULTS
DB fusion protein is expressed and folded. Following coexpres-
sion with the Shigella chaperone protein IpgC, the DB fusion was
isolated using the mild nonionic detergent OPOE, resulting in a
dominant 101.2-kDa product comprised of both IpaD and IpaB
(Fig. 1B). Like IpaB, the isolated DB fusion remains soluble in
buffer containing 0.5% OPOE. Far-UV circular-dichroism (CD)
measurements of IpaD, IpaB, and the DB fusion all showed spec-
tra exhibiting dominant minima at 208 and 222 nm, characteristic
of proteins with highly -helical secondary structures (Fig. 1C).
This suggests that the fusion maintained a proper and organized
secondary structure following purification and separation from
IpgC. The secondary-structure thermal stabilities for all three pro-
teins were determined using CD spectroscopy by monitoring
mean residue molar ellipticity at 222 nm as a function of temper-
ature. The resulting plots indicated a transition at 58°C for IpaB
and two transitions at 60°C and 80°C for IpaD (Fig. 1D), findings
in agreement with previously published data (13, 34). Interest-
ingly, the thermal unfolding curve for the DB fusion protein ex-
hibits characteristics intermediate to both IpaD and IpaB, with a
major transition at 60°C and a minor one around 78°C. Further-
more, the DB fusion mean residue molar ellipticity values for both
the far-UV scans and the thermal unfolding curves lie between
those for IpaD and IpaB alone, further suggesting that the IpaD
and IpaB domains of the fusion protein both maintain a substan-
tial portion of their original structural characteristics.
DB fusion protein generates antibody titers similar to those
generated by the combination of IpaB and IpaD. Mice were vac-
cinated intranasally three times, at days 0, 14, and 28, and serum
titers of IgG against IpaB and IpaD were determined by ELISA
(Fig. 2A and B). The titers of antibody against IpaB and IpaD
elicited by the DB fusion in the presence of dmLT were compara-
ble to those generated by vaccination with IpaB and IpaD with
dmLT. The peak antibody levels and the kinetics follow very sim-
ilar patterns, with no significant differences observed over time. In
both cases, IpaD responses were delayed until day 28 (after two
immunizations). Although the DB fusion protein administered
without dmLT is able to generate detectable antibodies against
IpaB and IpaD, adjuvant is required for generation of consistent
titers higher than 103 to 104 EU/ml. No specific IgG was detected
in mice immunized with PBS.
To assess the intestinal mucosal antibody responses, fecal IgA
antibody titers were determined by ELISA (Fig. 2C and D). Both
the DB fusion and the combination of IpaB and IpaD adminis-
tered with dmLT elicited specific IgA titers in stool. IgA antibodies
against IpaB were detected in the group immunized with the DB
fusion with adjuvant at day 28, one time point ahead of the group
that received IpaB and IpaD. The stool IgA titer was 10-fold higher
for IpaB than for IpaD in the DB fusion group, and the IpaD
antibodies were not detected until day 42 rather than at day 28, as
was the case for the IpaB antibodies. No stool IgA specific for these
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proteins was detected in the group immunized with the DB fusion
without dmLT or in the group immunized with PBS.
The DB fusion protein generates ASCs. At day 56, the fre-
quency of IgG- and IgA-secreting cells specific for each antigen
was determined by ELISPOT assay. In the lungs (Fig. 3A), the
frequency of ASCs specific for IpaB was higher for the DB Fusion
plus dmLT, especially for IgA-secreting cells. This tendency was
also observed for ASCs specific for IpaD. Only IgG-secreting cells
specific for IpaB were detected in lungs from mice immunized
with the DB fusion without adjuvant. In spleens (Fig. 3B), we
found a higher frequency of IgA-secreting cells specific for IpaB
than IgG-secreting cells, and when the groups that received IpaB
plus IpaD and the DB fusion are compared, no major differences
are observed. In general, the responses against IpaB were higher
than responses against IpaD in spleens. The DB fusion without
dmLT failed to elicit ASCs in the spleens. Finally, the frequencies
of ASCs in the bone marrow (Fig. 3C) specific for IpaB were higher
in the group that received IpaB plus IpaD plus dmLT, while for
IpaD a higher IgA response was observed in the group that re-
ceived the DB fusion plus dmLT. For this organ, a more balanced
IgG/IgA response was observed.
The DB fusion protein generates higher frequencies of spe-
cific IFN--secreting cells. The frequency of gamma interferon
(IFN-)-secreting cells was analyzed by ELISPOT assay using cells
extracted from spleens of immunized mice at day 56 (Fig. 4). The
DB fusion plus dmLT elicited higher numbers of specific IFN--
secreting cells than did IpaB plus IpaD plus dmLT. This was more
evident for IpaD-specific IFN--secreting cells, for which a 3-fold-
higher frequency was seen in the group that received the DB fusion
plus dmLT (20 SFC/106 cells for IpaB plus IpaD plus dmLT,
compared to 70 SFC/106 cells for the DB fusion plus dmLT).
The DB fusion without dmLT failed to generate IpaB-specific
IFN--secreting cells but managed to elicit a moderate number of
IpaD-specific IFN--secreting cells. No specific IFN--secreting
cells were detected in mice treated with PBS.
DB fusion protein generates a distinct profile of cytokine se-
cretion. Spleen cells were stimulated with IpaB or IpaD and the
resulting supernatants analyzed for cytokine secretion. IL-2 levels
varied depending on the antigen used for stimulation (Fig. 5A).
For IpaB, the group that received the DB fusion plus dmLT
showed higher cytokine secretion levels than the group that re-
ceived IpaB plus IpaD plus dmLT. The opposite was observed for
IpaD, for which cells obtained from animals that received IpaB
plus IpaD plus dmLT secreted higher levels of IL-2 than cells ob-
tained from animals that received the DB fusion plus dmLT. For
IL-4, cells from mice that were vaccinated with IpaB plus IpaD
plus dmLT showed higher cytokine secretion when stimulated
with either IpaB or IpaD (Fig. 5B). In contrast, no significant
differences were detected in levels of IL-5 secretion between the
groups immunized with IpaB plus IpaD plus dmLT or the DB
fusion plus dmLT (Fig. 5C). Secretion of the KC chemokine in
response to IpaB was higher in cells from mice that received the
DB fusion plus dmLT, with no differences being observed between
these two treatments when IpaD was used to stimulate these cells
(Fig. 5D). In the case of tumor necrosis factor alpha (TNF-),
significant differences were detected when IpaD was used to stim-
ulate these cells, with the mice immunized with the DB fusion plus
dmLT showing a greater response (Fig. 5E). In contrast, no differ-
ences in TNF- secretion were observed with IpaB stimulation.
Levels of IL-17 secretion in response to IpaB and IpaD stimulation
of spleen cells were also measured (Fig. 6). Cells from mice that
received the DB fusion plus dmLT secreted larger amounts of
IL-17 in response to IpaB than cells from mice that received IpaB
plus IpaD plus dmLT.
DB fusion protein protects against Shigella homologous and
heterologous challenges. At day 56, vaccinated animals (n  10
FIG 2 Serum IgG titer kinetics. Mice were vaccinated three times, at the time points indicated by the arrows. Blood samples were collected and serum was
separated. IgG antibodies specific for IpaB (A) or IpaD (B) were measured by ELISA. The individual titers are represented as EU ml	1, and each point represents
mean 
 SD of 10 mice per group. *, P  0.05 comparing groups that received IpaB plus IpaD plus dmLT and the DB fusion plus dmLT using t test. IgA antibodies
specific for IpaB (C) or IpaD (D) were measured by ELISA. The pool titers are represented as EU ml	1, and each point represents pooled samples of 10 mice per
group.
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per bacterial strain) were challenged with S. flexneri 2a, S. sonnei,
or S. dysenteriae, and protection was monitored for 14 days after
infection. For the homologous challenge using S. flexneri, mice
that received IpaB plus IpaD plus dmLT showed a protection level
of 90%, while the mice that received the DB fusion plus dmLT
showed a protection level of 70%. Mice that received the DB fusion
without dmLT showed 20% protection after 14 days. No protection
was observed for mice immunized with PBS (Fig. 7A). When S. sonnei
was used to challenge vaccinated animals, we observed 100% protec-
tion in animals vaccinated with IpaB plus IpaD plus dmLT or the DB
fusion plus dmLT. Mice that received the DB fusion alone showed
80% protection, while mice treated with PBS showed 20% protec-
tion. These numbers result in a calculated vaccine efficacy of 80% for
both groups that received vaccine formulated with dmLT, and 55%
for the group that received the DB fusion alone Fig. 7B). For S. dys-
enteriae, the group that received IpaB plus IpaD plus dmLT showed
FIG 4 IFN--secreting cells. Splenocytes obtained at day 56 from immunized
animals were incubated with 10 g/ml of IpaB and IpaD. IFN--secreting cells
were determined by ELISPOT, and SFC per 106 cells were calculated and plot-
ted as means 
 SD of quadruplicate wells. *, P  0.05 comparing groups that
received IpaB plus IpaD plus dmLT and the DB fusion plus dmLT using t test.
FIG 3 Antibody-secreting cells. Immunized mice (n  5 per group) were euthanized at day 56 and organs were collected. Single-cell suspensions obtained from
lungs (A), spleen (B), and bone marrow (C) were incubated in plates with IpaB or IpaD. IgG- and IgA-secreting cells were detected by ELISPOT assay and plotted
as mean specific ASCs per 106 cells 
 SD. *, P  0.05 comparing groups that received IpaB plus IpaD plus dmLT and DB Fusion plus dmLT using t test.
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only 10% protection, while the group that received the DB fusion plus
dmLT showed a protection level of 40%. No protection was observed
in mice vaccinated with the DB fusion without dmLT or in mice that
received PBS (Fig. 7C).
DISCUSSION
Despite progress using different approaches, a Shigella vaccine is
still not available. When the main target group for a Shigella vac-
cine is children living in developing countries, variables that im-
pact the cost of production should be evaluated to diminish the
vaccine cost. Taking this into consideration, we generated a fusion
protein consisting of IpaD and IpaB. The DB fusion shared char-
acteristics of IpaB. DB fusion expression was achieved only in the
presence of IpaB’s chaperone, IpgC, which is removed using 0.5%
OPOE during chromatography purification. Although this indi-
cates that the IpaD portion of the DB fusion is not sufficient to
generate an independently soluble polypeptide, the subsequent
purification step allows for a highly pure protein. Therefore, this
purification step may be advantageous. Additionally, the DB fu-
sion maintains a highly -helical secondary structure in solution,
with a stability similar to that of IpaB. While IpaD undergoes two
thermal transitions, these transitions are not seen in the DB fu-
sion. After three immunizations with equimolar concentrations,
the DB fusion plus dmLT was able to elicit titers of serum IgG and
stool IgA against both IpaB and IpaD at a magnitude similar to
that elicited by administering the combination of IpaB and IpaD
with dmLT. Therefore, recognition and generation of antibody
responses against the components of the DB fusion remain at
comparable levels. The presence of antibody-secreting cells in the
same organ compartments supports this statement. Both IgG- and
IgA-secreting cells were observed in the lungs, spleens, and bone
marrow, specific for both IpaB and IpaD. The differences ob-
served in the frequencies of ASCs, however, suggest that there are
some small differences in how the proteins are able to activate B
cells, which could impact the fate and distribution of plasmatic
and memory cells. While mice immunized with the DB fusion plus
dmLT showed higher frequencies of ASCs in the lungs and
spleens, a lower frequency was observed in the bone marrow, sug-
FIG 5 Cytokines. Splenocytes obtained at day 56 from immunized animals were
incubated with 10 g/ml of IpaB and IpaD. After 48 h, supernatants were collected
and levels of cytokine secretion in response to IpaB (left) and IpaD (right) were
then measured (in pg/ml) using a cytokine detection plate. Each bar represents the
mean of quadruplicate wells 
 SD. *, P  0.05 comparing groups that received
IpaB plus IpaD plus dmLT and the DB fusion plus dmLT using t test.
FIG 6 IL-17 secretion. Splenocytes obtained at day 56 from immunized ani-
mals were incubated with 10 g/ml of IpaB and IpaD. After 48 h, supernatants
were collected and levels of IL-17 secretion were measured using an ELISA kit.
Each bar represents the mean of quadruplicate wells 
 SD. *, P  0.05 com-
paring groups that received IpaB plus IpaD plus dmLT and the DB fusion plus
dmLT using t test.
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gesting differences in effector versus long-term memory ratios.
Although the DB fusion without dmLT was able to elicit serum
IgG responses against IpaB and IpaD, these responses were of a
lower magnitude and highly variable between the individuals.
Furthermore, it failed to induce IgA secretion in stool and gener-
ation of specific cytokine-secreting cells. This highlights the re-
quirement of the dmLT adjuvant for these responses.
The analysis of the cytokine secretion profiles elicited by each
group showed some differences between the immunized groups.
Some cytokine responses were higher when the DB fusion was
used for immunization. In particular, the frequencies of IFN--
secreting cells and IL-17 secretion levels were higher in cells ob-
tained from mice immunized with the DB fusion. Even if dmLT
has the capacity of eliciting IL-17 responses by itself (36), the pres-
ence of the adjuvant in both formulations indicates the possibility
that the fusion could be recognized by the immune system in a
different manner than the individual proteins. Most importantly,
this demonstrates that the DB fusion has a unique advantage in the
generation of cell-mediated immunity, which can be important
for control of Shigella. Indeed, both IFN- and IL-17 have been
described as important cytokines during Shigella infection (37,
38). The challenge experiments show that both proteins are able to
provide heterologous protection. In the case of S. dysenteriae, only
the DB fusion with dmLT was able to provide significant protec-
tion. This particular challenge is more stringent, as we used a
strain that expresses Shiga toxin. The ability of the DB fusion to
protect in contrast to the combination of IpaB and IpaD could be
related to the cytokine profile elicited by this protein. Even with
this tendency of higher protection with higher cytokine secretion,
the role of antibodies cannot be ruled out. The protective efficacy
of the DB fusion without adjuvant in the S. sonnei challenge could,
then, relate to antibodies generated by this protein. Even if hu-
moral responses could be less involved in protection, we still de-
tected a 55% protective efficacy. This was probably observed only
for S. sonnei given that the challenge dose that was used is lower
than for S. flexneri and S. dysenteriae. In conclusion, we provide
evidence that a fusion protein comprised of IpaB and IpaD is able
to generate immune responses against the two subcomponents,
retaining heterologous protection capabilities and generating
higher IFN- and IL-17 responses, which could be important for
protection against shigellosis in humans.
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